Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

10TC

Structure of WDR5 bound to RbBP5 (D376N)

Summary for 10TC
Entry DOI10.2210/pdb10tc/pdb
DescriptorWD repeat-containing protein 5, RbBP5 (3 entities in total)
Functional Keywordshistone, epigenetic, peptide binding protein
Biological sourceHomo sapiens (human)
More
Total number of polymer chains8
Total formula weight137608.00
Authors
Gregoire, S.,Couture, J.F. (deposition date: 2026-02-07, release date: 2026-05-20)
Primary citationGregoire, S.,Chow, S.,Joshi, M.,Zhang, P.,Ahmad, A.A.,Janna, A.,Tremblay, V.,Munoz, M.,Mer, A.,Couture, J.F.
Probing the Cancer Mutational Landscape of KMT2 Regulatory Subunits.
Faseb J., 40:e71745-e71745, 2026
Cited by
PubMed Abstract: Members of the Lysine MethylTransferase 2 (KMT2) family are often abnormally expressed and mutated in many cancers. Similarly, several mutations listed in cancer databases map to key functional regions of KMT2 regulatory subunits, such as WD repeat domain 5 (WDR5), Retinoblastoma binding protein 5 (RbBP5), absent-small-homeotic-2-like (ASH2L), and DumPY-30 (DPY-30). In this study, we report the systematic characterization of cancer-associated mutations that map to regions important for the WDR5/RbBP5/ASH2L/DPY-30 (WRAD) complex formation. Both binding and thermal stability assays show that several cancer-related mutations do not affect ASH2L binding to DPY-30 or RbBP5. A subset of gain-of-function mutants highlights the role of long-range networks of interactions underlying RbBP5 binding by ASH2L. Parallel analysis of RbBP5 mutations shows additional variants that weaken its interactions with WDR5. Finally, systematic mapping of RbBP5 residues interacting with WDR5 defines the optimal WDR5-binding motif and shows that introducing hydrophobic residues beyond the central VDV sequence increases binding affinity. Overall, these findings reveal surprising gain-of-function mutations in ASH2L and provide a framework for targeting this epigenetic hub therapeutically.
PubMed: 41949561
DOI: 10.1096/fj.202504644R
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.2 Å)
Structure validation

253795

PDB entries from 2026-05-20

PDB statisticsPDBj update infoContact PDBjnumon